Janus Henderson Group PLC Acquires 21,709 Shares of Medpace Holdings, Inc. $MEDP

Janus Henderson Group PLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 21.0% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 124,954 shares of the company’s stock after acquiring an additional 21,709 shares during the quarter. Janus Henderson Group PLC’s holdings in Medpace were worth $60,026,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MEDP. AQR Capital Management LLC grew its holdings in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after acquiring an additional 324,293 shares during the period. Wasatch Advisors LP raised its position in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares during the period. Invesco Ltd. lifted its stake in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after purchasing an additional 38,760 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Medpace news, CEO August J. Troendle sold 3,728 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $600.85, for a total value of $2,239,968.80. Following the completion of the transaction, the chief executive officer directly owned 642,456 shares of the company’s stock, valued at approximately $386,019,687.60. The trade was a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares of the company’s stock, valued at $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 31,087 shares of company stock worth $16,203,054. Corporate insiders own 20.50% of the company’s stock.

Medpace Stock Down 0.2%

Shares of NASDAQ MEDP opened at $577.11 on Friday. The company’s fifty day moving average is $507.61 and its 200-day moving average is $493.77. The stock has a market cap of $16.11 billion, a price-to-earnings ratio of 33.83, a P/E/G ratio of 2.57 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the business earned $3.10 EPS. The firm’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Robert W. Baird raised their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.